DICE - DICE Therapeutics GAAP EPS of -$0.54
2023-05-11 18:13:57 ET
- DICE Therapeutics press release ( NASDAQ: DICE ): Q1 GAAP EPS of -$0.54.
- Cash Position: Cash, cash equivalents and marketable securities totaled $554.5 million at March 31, 2023.
- R&D Expenses: Research and development expenses were $23.7 million for the first quarter of 2023, compared to $13.4 million for the same period in 2022.
- Net loss totaled $25.6 million and $18.6 million for the first quarters of 2023 and 2022, respectively, with non-cash stock-based compensation expense of $4.9 million and $1.8 million for the first quarters of 2023 and 2022, respectively.
For further details see:
DICE Therapeutics GAAP EPS of -$0.54